Skip to main content
Admissions guidance, study banks, and career tools — get started on Shalyam
Research News

Vitamin C May Help Prevent Blood Cancer in Some People

Mayur Tembhare
  1. participants were studied in Denmark and the US for 12 months.

  2. Half of the participants took 1,000 mg of vitamin C every day, while the other half got a placebo.

  3. People taking vitamin C had fewer serious health problems, such as anemia and pneumonia.

  4. The study found that people taking vitamin C were more likely to survive during follow-up.

Vitamin C May Help Prevent Blood Cancer in Some People

Topic: Health

A clinical trial found that vitamin C supplements may help people with certain blood disorders live longer. Researchers studied 109 participants in Denmark and the US for 12 months, giving some a daily dose of 1,000 mg of vitamin C. The results showed that those taking vitamin C had fewer serious health problems and were more likely to survive.

Researchers wanted to see if vitamin C could help people with blood disorders that might turn into cancer. They chose 109 participants in Denmark and the US who had either a blood disorder or low-risk blood cancer. The participants were divided into two groups: one group took 1,000 mg of vitamin C every day for 12 months, while the other group got a placebo.

The researchers looked at how well the vitamin C worked by measuring things like cell growth and inflammation. They found that people taking vitamin C had fewer serious health problems, such as anemia and pneumonia. However, they also experienced more gastrointestinal problems.

After 33.6 months, 35 participants had died. Of those deaths, 24 occurred in the placebo group and 11 occurred in the vitamin C group. The researchers found that people taking vitamin C were more likely to survive during follow-up. But they emphasized that this was an exploratory finding and needed to be confirmed in a larger trial.

The study's lead researcher, Peter A. Jones, said that the results give them a 'strong rationale' to continue exploring if vitamin C can benefit people with certain pre-cancer or early-stage blood cancers.

Why It Matters

This research is important because it could help us find new ways to prevent and treat blood cancer in India. Blood cancer is a major health problem in our country, and any breakthroughs in this area could save many lives.

Key Facts

  • 109 participants were studied in Denmark and the US for 12 months.
  • Half of the participants took 1,000 mg of vitamin C every day, while the other half got a placebo.
  • People taking vitamin C had fewer serious health problems, such as anemia and pneumonia.
  • The study found that people taking vitamin C were more likely to survive during follow-up.
  • A larger trial is needed to confirm these findings.

Key Terms

TET enzymes
Proteins that help regulate whether certain genes are switched on or off.
Epigenetics
The study of how environmental factors affect gene expression without changing the DNA sequence itself.
Clonal cytopenia of undetermined significance (CCUS)
A blood disorder that may develop into cancer, but its cause is unknown.

Implications

This research is important because it could help us find new ways to prevent and treat blood cancer in India. Blood cancer is a major health problem in our country, and any breakthroughs in this area could save many lives.

Source: https://www.sciencedaily.com/releases/2026/09/260930225454.htm

Journal reference:

  1. Stine Ulrik Mikkelsen, Ali Al‐Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial. Cancer, 2026; 132 (19) DOI: 10.1002/cncr.70549

Leave a comment

← All research

Get Exclusive Insights with Every Issue

Join Shalyam Newsletter

Stay ahead in education, research, and innovation—straight to your inbox.